EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Essential role of MHC II in the antitubercular efficacy of pyrazinamide

Elise A Lamont iD, Shannon L Kordus iD, Michael D Howe, Ziyi Jia iD, Nathan Schacht iD, Muzafar Ahmad Rather iD, Gebremichal Gebretsadik iD, Anthony D Baughn iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01264-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Elise A Lamont und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Pyrazinamide, Mycobacterium tuberculosis, Antitubercular Agents, Histocompatibility Antigens Class II. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibacterial drug mechanisms have traditionally been examined through a drug-pathogen lens, with limited attention to host influences on drug activity. However, growing evidence suggests that the host environment is crucial for antibacterial efficacy. Pyrazinamide (PZA), a key component of modern tuberculosis therapy, exemplifies this complexity, exhibiting potent in vivo activity despite its inability to reduce Mycobacterium tuberculosis viability in standard in vitro culture. Here, using macrophage and murine infection models, we identify a critical role for CD4 + T cell-dependent cell-mediated immunity in PZA’s antitubercular action. Using MHC class II knockout mice, we demonstrate that CD4 T-cell help is essential for PZA efficacy. While interferon gamma (IFN-γ) is required for PZA-mediated clearance of M. tuberculosis at extrapulmonary sites, bacterial reduction in the lungs occurs, independent of IFN-γ signaling. We show that PZA leverages cell-mediated immunity in part through activation of the oxidative burst. Our findings underscore the need to incorporate host factors into antibacterial drug evaluation and highlight potential avenues for host-directed therapies and adjunctive antibiotics in first- and second-line tuberculosis treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazinamideMycobacterium tuberculosisAntitubercular AgentsHistocompatibility Antigens Class IIAnimalsMiceInterferon-gammaMice, KnockoutCD4-Positive T-LymphocytesMacrophagesMice, Inbred C57BLImmunity, CellularLungTuberculosisFemale

Stichwörter der Autor:innen

CD4 T cellsMHC IIMycobacterium tuberculosisinterferon-gammaoxidative burstpyrazinamide

Substanzen

PyrazinamideAntitubercular AgentsInterferon-gammaHistocompatibility Antigens Class II

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Elise A Lamont, Shannon L Kordus, Ziyi Jia, Nathan Schacht, Muzafar Ahmad Rather, Gebremichal Gebretsadik, Anthony D Baughn

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Lamont, E. A., Kordus, S. L., Howe, M. D., Jia, Z., Schacht, N., Rather, M. A., Gebretsadik, G., & Baughn, A. D. (2026). Essential role of MHC II in the antitubercular efficacy of pyrazinamide. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01264-25

Vancouver

Lamont EA, Kordus SL, Howe MD, Jia Z, Schacht N, Rather MA, et al. Essential role of MHC II in the antitubercular efficacy of pyrazinamide. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01264-25

BibTeX
@article{Lamont2026,
  author = {Lamont, Elise A and Kordus, Shannon L and Howe, Michael D and Jia, Ziyi and Schacht, Nathan and Rather, Muzafar Ahmad and Gebretsadik, Gebremichal and Baughn, Anthony D},
  title = {Essential role of MHC II in the antitubercular efficacy of pyrazinamide},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01264-25}
}
Kostenlos starten →